Related Experiment Video
Updated: Aug 7, 2026
09:44
Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
Published on: June 13, 2021
Serum repressing efflux pump CDR1 in Candida albicans
Yun-Liang Yang1, Yi-Hsuan Lin, Ming-Yang Tsao
1Department of Biological Science and Technology, National Chiao Tung University, Hsinchu. yyang@mail.nctu.edu.tw
BMC Molecular Biology
|July 15, 2006
Summary
Human serum surprisingly represses the CDR1 gene in Candida albicans, a key factor in antifungal drug resistance. This finding challenges standard in vitro testing for predicting treatment outcomes in candidemia.
Area of Science:
- Mycology
- Molecular Biology
- Antimicrobial Resistance
Background:
- Candidemia prevalence and antifungal drug resistance are increasing concerns.
- Overexpression of the CDR1 efflux pump is a major mechanism of drug resistance in Candida albicans.
- Biological fluids like human serum can significantly impact antifungal drug effectiveness.
Purpose of the Study:
- To investigate the effect of human serum on the drug susceptibility of Candida albicans.
- To monitor the activity of the CDR1 promoter in response to serum exposure.
Main Methods:
- Construction of a CDR1 promoter-Renilla luciferase (CDR1p-RLUC) reporter system in wild-type and cdr1/cdr1 mutant Candida albicans.
- Monitoring CDR1 promoter activity and CDR1 mRNA levels in the presence of serum and other inducers (miconazole, N-acetyl-D-glucosamine).
- Assessing antifungal drug susceptibility in wild-type and mutant strains with and without serum.
Main Results:
- Wild-type Candida albicans showed increased susceptibility to antifungal drugs in serum-containing medium.
- CDR1 promoter activity and CDR1 mRNA levels were repressed by serum, contrary to miconazole-induced expression.
- N-acetyl-D-glucosamine did not affect CDR1 expression, unlike serum.
Conclusions:
- Serum represses CDR1 expression in Candida albicans, questioning its role in serum-mediated drug resistance.
- Standard in vitro antifungal susceptibility testing, typically performed without serum, may not accurately predict in vivo therapeutic outcomes for candidemia.
- Further research is needed to understand the mechanisms underlying serum's effect on CDR1 and its clinical implications.
Related Concept Videos
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...